Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets
Launched by NATIONAL CENTER FOR RESEARCH RESOURCES (NCRR) · Nov 3, 1999
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed with Congenital Adrenal Hyperplasia (CAH)
- • normal ECG during baseline evaluation
- Exclusion Criteria:
- • history of liver disease, or elevated liver function tests
- • history of cardiovascular disease
About National Center For Research Resources (Ncrr)
The National Center for Research Resources (NCRR), part of the National Institutes of Health (NIH), is dedicated to enhancing the nation's capacity to conduct biomedical research through the support of innovative research infrastructure and resources. NCRR plays a pivotal role in promoting the development and application of cutting-edge technologies and methodologies that facilitate the advancement of clinical and translational research. By funding programs and initiatives that foster collaboration among researchers, institutions, and communities, NCRR aims to improve the quality and efficiency of research, ultimately leading to better health outcomes and discoveries that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials